Breaking News, Collaborations & Alliances

Pii Inks Devt. Deal with Nemus

CDMO to develop dosage formulation for human dosing with NB1111 for glaucoma

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Nemus Bioscience has signed an agreement with Pharmaceuticals International Inc. (Pii), a contract development manufacturing organization (CDMO) to develop a sterile eyedrop dosage formulation of NB1111 for human dosing. NB1111 is Nemus’ proprietary prodrug of tetrahydrocannabinol (THC) that is currently undergoing development for the treatment of glaucoma.   “Pii is an experienced formulator of ocular-based therapies and we look forward to working with them, and our discovery and research colle...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters